Shareholder voteRegulatory filing
What was reported
On June 9, 2026, Intellia Therapeutics, Inc. (the "Company") held its Annual Meeting to consider and vote on the three proposals set forth below, each of which is described in detail in the Proxy Statement. The following is a summary of the matters voted on at the Annual Meeting.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jun 10, 2026 · Open the source ↗
What the evidence supports
Intellia Therapeutics told the SEC (Form 8-K, Item 5.07) that its shareholders voted on matters put to them, and what the outcome was. The filing gives Jun 9, 2026 as the date of the earliest event reported.
What remains unknown
How individual shareholders voted, and what the company will do next beyond what it disclosed.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.07 textOn June 9, 2026, Intellia Therapeutics, Inc. (the "Company") held its Annual Meeting to consider and vote on the three proposals set forth below, each of which is described in detail in the Proxy Statement. The following is a summary of the matters voted on at the Annual Meeting.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jun 10, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Intellia Therapeutics reports results of a shareholder vote (Form 8-K, Item 5.07)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.